Advertisement
Skip to Content

Dechra Pharmaceuticals PLC DCHPF Stock Quote

| Rating as of

GREY: DCHPF

Last close prices updated as of Jan 24, 2023, 2:43 PM EST | USD
  • Last Close 32.5
  • Sector Healthcare
  • Industry Drug Manufacturers - General
  • Investment Style Mid Growth
  • Day Range 32.50  –  32.50
  • Year Range 27.90  –  54.93
  • Market Cap 3.6997 Bil
  • Volume / Avg 500.0 /  1,107.0
  • Price / Sales 4.18
  • Price / Book 4.47
  • Forward Div Yield 1.69%
  • Trailing Div Yield 1.38%

Morningstar‘s Stock Analysis DCHPF

Valuation
Currency in
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price

INVESTOR

5-Star Price

INVESTOR

Economic Moat

INVESTOR

About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics DCHPF

Company Profile DCHPF

Business Description

Dechra Pharmaceuticals PLC is a major drug manufacturing company with a focus on veterinary pharmaceutical products. The company develops, manufactures, and markets its products exclusively for veterinarians globally. Dechra is structured along three segments, including being European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals Research and Development. The vast majority of Dechra's revenue is generated in Europe, followed by the U.S. Dechra derives most of its revenue through its Companion Animal Product category, followed by food-producing animal products.

Contact
24 Cheshire Avenue, Cheshire Business Park, Lostock Gralam
Northwich, CW9 7UA, GBR
Industry Drug Manufacturers - General
Employees 2,036

FAQs for Dechra Pharmaceuticals PLC Stock

No. DCHPF does not currently have a forward dividend yield.
Dividend yield allows investors, particularly those interested in dividend-paying stocks, to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.

Learn more about dividend yield.

DCHPF’s market cap is 3.70 Bil.
Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares. It’s often used to measure a company’s size. In the Morningstar Style Box, large-cap names account for the largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies.

Learn more about market capitalization.

DCHPF’s stock style is Mid Growth.
Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated.

High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends.

Learn more about style.

DCHPF’s beta can be found in Trading Information at the top of this page.
A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.

Compare DCHPF’s historical performance against its industry peers and the overall market.